Show simple item record

dc.contributor.authorDziadziuszko, R.
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorDe Braud, F.
dc.contributor.authorSiena, S.
dc.contributor.authorDrilon, A.
dc.contributor.authorDoebele, R. C.
dc.contributor.authorPatel, M. R.
dc.contributor.authorCho, B. C.
dc.contributor.authorLiu, S. V.
dc.contributor.authorAhn, M. J.
dc.contributor.authorChiu, C. H.
dc.contributor.authorFarago, A. F.
dc.contributor.authorLin, C. C.
dc.contributor.authorKarapetis, C. S.
dc.contributor.authorLi, Y. C.
dc.contributor.authorDay, B. M.
dc.contributor.authorChen, D.
dc.contributor.authorWilson, T. R.
dc.contributor.authorBarlesi, F.
dc.date.accessioned2021-04-06T15:07:07Z
dc.date.available2021-04-06T15:07:07Z
dc.date.issued2021en
dc.identifier.citationDziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, et al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021:JCO2003025.en
dc.identifier.pmid33646820en
dc.identifier.doi10.1200/jco.20.03025en
dc.identifier.urihttp://hdl.handle.net/10541/623874
dc.description.abstractPurpose: Genetic rearrangements of the tyrosine receptor kinase ROS proto-oncogene 1 (ROS1) are oncogenic drivers in non-small-cell lung cancer (NSCLC). We report the results of an updated integrated analysis of three phase I or II clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2) of the ROS1 tyrosine kinase inhibitor, entrectinib, in ROS1 fusion-positive NSCLC. Methods: The efficacy-evaluable population included adults with locally advanced or metastatic ROS1 fusion-positive NSCLC with or without CNS metastases who received entrectinib ≥ 600 mg orally once per day. Co-primary end points were objective response rate (ORR) assessed by blinded independent central review and duration of response (DoR). Secondary end points included progression-free survival (PFS), overall survival (OS), intracranial ORR, intracranial DoR, intracranial PFS, and safety. Results: In total, 161 patients with a follow-up of ≥ 6 months were evaluable. The median treatment duration was 10.7 months (IQR, 6.4-17.7). The ORR was 67.1% (n = 108, 95% CI, 59.3 to 74.3), and responses were durable (12-month DoR rate, 63%, median DoR 15.7 months). The 12-month PFS rate was 55% (median PFS 15.7 months), and the 12-month OS rate was 81% (median OS not estimable). In 24 patients with measurable baseline CNS metastases by blinded independent central review, the intracranial ORR was 79.2% (n = 19; 95% CI, 57.9 to 92.9), the median intracranial PFS was 12.0 months (95% CI, 6.2 to 19.3), and the median intracranial DoR was 12.9 months (12-month rate, 55%). The safety profile in this updated analysis was similar to that reported in the primary analysis, and no new safety signals were found. Conclusion: Entrectinib continued to demonstrate a high level of clinical benefit for patients with ROS1 fusion-positive NSCLC, including patients with CNS metastases.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/jco.20.03025en
dc.titleUpdated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small-cell lung canceren
dc.typeArticleen
dc.contributor.departmentMedical University of Gdańsk, Gdańsk, Polanden
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]
refterms.dateFOA2021-04-07T09:47:50Z


Files in this item

Thumbnail
Name:
33646820.pdf
Size:
399.6Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record